Acrivon Therapeutics (ACRV) Current Leases (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Current Leases of $1.2 million for Q1 2026, up 4.25% year-over-year from $1.1 million in Q1 2025, and down 1.71% quarter-over-quarter from $1.2 million in Q4 2025.
Acrivon Therapeutics (ACRV) Current Leases (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Current Leases for 6 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 4.25% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (up 4.25% YoY), while the FY2025 annual figure was $1.2 million, up 10.88% from the prior year.
- Current Leases slipped to $1.2 million in Q1 2026 per ACRV's latest filing, from $1.2 million in the prior quarter.
- Across five years, Current Leases topped out at $1.2 million in Q3 2025 and bottomed at $717000.0 in Q3 2022.
- Historically, Current Leases has averaged $957933.3 across 5 years, with a median of $978000.0 in 2024.
- Annual changes were most pronounced in 2024 — Current Leases soared 34.02% — and 2026, when it increased 4.25%.
- Acrivon Therapeutics' Current Leases stood at $726000.0 in 2022, then climbed by 20.8% to $877000.0 in 2023, then gained by 20.52% to $1.1 million in 2024, then advanced by 10.88% to $1.2 million in 2025, then slipped by 1.71% to $1.2 million in 2026.
- Business Quant data shows ACRV's Current Leases at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | 1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 978,000.00 |
| Mar 31, 2024 | 944,000.00 |
| Dec 31, 2023 | 877,000.00 |
| Sep 30, 2023 | 776,000.00 |
| Jun 30, 2023 | 753,000.00 |
| Mar 31, 2023 | 740,000.00 |
| Dec 31, 2022 | 726,000.00 |
| Sep 30, 2022 | 717,000.00 |
| Dec 31, 2021 | 664,000.00 |